|
Impaired cognition
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data also indicate that introduction of the Swedish mutation alone in endogenous APP is not sufficient to produce either AD-related brain pathology or cognitive deficits in mice.
|
30894120 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate the relationship between cerebrospinal fluid (CSF) β-amyloid peptide (Aβ42) and CSF Tau in a large population of patients referred to memory clinics for investigation of cognitive dysfunction.
|
31086391 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-181a protects against pericyte apoptosis via directly targeting FOXO1: implication for ameliorated cognitive deficits in APP/PS1 mice.
|
31467256 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Further, Morris water maze (MWM) testing data indicated that LPS administration acutely aggravated cognitive impairment in APP/PS1 mice, suggesting that the addition of systemic inflammation can potentially accelerate the progression of AD.
|
30756214 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota.
|
30816709 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, compared to wild-type (WT) mice, while brain perfusion was similar in APP/PS1 mice fed with a chow diet, NAFLD in APP/PS1 mice reveals cerebral hypoperfusion and furthered cognitive decline.
|
31130652 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
To study the preventive effect of Rg1 on cognitive impairment and the possible mechanism, we established the cognitive impairment model in rats through Aβ<sub>1-42</sub> (2.6 µg/µL, 5 µL) injection and then treated the rats with Rg1 (25, 50 and 100 mg/kg) administered intragastrically for 4 weeks.
|
31016510 |
2019 |
|
Impaired cognition
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
At 9 months of age, untreated 3×Tg-AD mice vs. wild-type (WT) controls displayed cognitive deficits in behavioral assays and, at 12 months, elevated levels of hippocampal amyloid beta-protein (Aβ), amyloid precursor protein (APP), tau phosphorylation, and pro-inflammatory cytokines.
|
31603034 |
2019 |
|
Impaired cognition
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A Morris water maze test was performed and showed that overexpression of miR-361-3p improved cognitive deficits in APP/PS1 mice.
|
31601077 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study investigated the effect of chlorogenic acids on the prevention of cognitive dysfunction in APP/PS2 transgenic mouse model of Alzheimer's disease.
|
31121203 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previous studies indicated that BACE1 initially cleaves the amyloid precursor protein (APP) and may subsequently interfere with physiological functions of proteins such as PKA, which is recognized to be closely associated with long-term potentiation (LTP) level and can effectively ameliorate cognitive impairments.
|
31223308 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings show that the TIPE2 expression level was negatively correlated with the pathogenesis of Alzheimer's disease, and overexpression of TIPE2 attenuates cognitive deficits in APP/PS1 mice, suggesting TIPE2 is a potential target for pharmacological intervention and improvement of cognitive deficits.Graphical Abstract .
|
31286344 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Treadmill Exercise Decreases Aβ Deposition and Counteracts Cognitive Decline in APP/PS1 Mice, Possibly <i>via</i> Hippocampal Microglia Modifications.
|
31024293 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, the novel small molecule OAB-14, designed using bexarotene as the lead compound, significantly alleviated cognitive impairments in amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mice after administration for 15 days or 3 months.
|
30389579 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
The actions of PGA1 on the production and deposition of Aβ ultimately improved the cognitive decline of the amyloid precursor protein/presenilin1 (APP/PS1) transgenic mice.
|
30627958 |
2019 |
|
Impaired cognition
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The study suggests that both HIIT and MICT alleviate cognitive decline and down-regulat Aβ level in the hippocampus in APP/PS1 transgenic mice, which may be mediated by improvements in mitochondrial morphology and dynamics.
|
31445975 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of β-amyloid peptide.
|
31847879 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results indicate that NTP reduces neuroinflammation and improves the cognitive deficits in APP/PS1 mice possibly via BDNF/NF-κB pathway.
|
30972181 |
2019 |
|
Impaired cognition
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Due to having three copies of the amyloid precursor protein (APP) gene which results in amyloid-beta plaque deposition, the cognitive decline often resembles the decline observed in Alzheimer's disease.
|
30877730 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
In behavioral studies, SAR502250 improved the cognitive deficit in aged transgenic APP(SW)/Tau(VLW) mice or in adult mice after infusion of Aβ<sub>25-35</sub>.
|
31792284 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
As a result, the nanochaperone reduces Aβ burden, attenuates Aβ-induced inflammation, and eventually rescues the cognitive deficits of APP/PS1 transgenic AD mice.
|
31763156 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
The combination of indomethacin and atorvastatin restored immune and neuroendocrine processes, attenuated pathologic changes and cognitive impairments in APP/PS1 transgenic mice, and could thus be a potential therapeutic agent for AD.
|
30870684 |
2019 |
|
Impaired cognition
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, APP/PS1 mice had significantly lower SOD activity and higher malondialdehyde concentration than WT mice in the hippocampus (P < 0.0001), paralleled by apparent cognitive dysfunction.
|
31373375 |
2019 |
|
Impaired cognition
|
0.600 |
Biomarker
|
disease |
BEFREE |
The SUMO1-APP transgenics displayed normal APP processing but, at later ages, exhibited increased insoluble Aβ and plaque density accompanied by increased dendritic spine loss, more pronounced synaptic and cognitive deficits.
|
29217476 |
2018 |
|
Impaired cognition
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
An amyloid precursor protein (APP) A673T mutation was found to be protective against Alzheimer's disease (AD) and cognitive decline in the Icelandic population and to associate with decreased levels of plasma β-amyloid in a Finnish population-based cohort.
|
29807259 |
2018 |